81 results
8-K
EX-10.1
EYEG
EyeGate Pharmaceuticals, Inc.
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.2
EYEG
EyeGate Pharmaceuticals, Inc.
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
EYEG
EyeGate Pharmaceuticals, Inc.
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.2
5xv6 l73b
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-10.1
0id 4g82oe
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-10.3
t13mq9
3 Feb 23
Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital
7:01am
8-K
EX-10.4
1nt84 o94rbtlq2ut
3 Feb 23
Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital
7:01am
8-K
EX-10.1
e11w otktctbu
3 Feb 23
Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital
7:01am
8-K
EX-10.2
ckqw4
3 Feb 23
Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital
7:01am
8-K
EX-10.1
8pk2b 4bxx0
21 Nov 22
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million
7:00am
8-K
EX-10.1
0c33ky
16 Sep 22
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
4:30pm
8-K
EX-10.1
qlciy
26 Apr 22
Departure of Directors or Certain Officers
6:51am
8-K
EX-10.1
ej046tc6wdah2cj nv
1 Feb 22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
6:45am
8-K
EX-10.1
dpndh5 duzk3dhzgd
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-10.1
zs928ipf
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.2
ne8e6l76w
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
9hf8tbwc2afelibv0t
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm